Zhang Yongqiang, Xie Yong, Zhang Chunyu, Wang Jianglin, Liao Bin, Feng Jian
Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, Luzhou, Sichuan, China.
Department of Cardiology, Hejiang County People's Hospital, Luzhou, Sichuan, China.
Curr Vasc Pharmacol. 2024 Nov 5. doi: 10.2174/0115701611328810241028112700.
Contrast-induced Acute Kidney Injury (CI-AKI) frequently occurs as a complication following PCI, making the identification of high-risk patients challenging. While the systemic immune inflammation index (SII) might aid in predicting CI-AKI, the current evidence remains insufficient.
We conducted a systematic literature search using PubMed, Web of Science, Embase, and the Cochrane Library, with a cut-off date of 3/20/2024. We included observational studies that examined the predictive value of SII for the risk of CI-AKI.
This meta-analysis encompassed 8 studies with a combined total of 6301 participants. Results showed pooled sensitivity and specificity of 0.73 (95% CI 0.69-0.76) and 0.68 (95% CI 0.57- 0.77), respectively. The sROC curve analysis indicated an AUC of 0.74 (95% CI 0.70-0.78). The risk of publication bias was low (p = 0.18).
The results of this study suggest that SII has a relatively high sensitivity and could function as a biomarker for the prediction of CI-AKI risk in people receiving PCI treatment.
造影剂诱导的急性肾损伤(CI-AKI)常作为PCI术后的并发症出现,这使得识别高危患者具有挑战性。虽然全身免疫炎症指数(SII)可能有助于预测CI-AKI,但目前的证据仍然不足。
我们使用PubMed、Web of Science、Embase和Cochrane图书馆进行了系统的文献检索,截止日期为2024年3月20日。我们纳入了观察性研究,这些研究探讨了SII对CI-AKI风险的预测价值。
这项荟萃分析涵盖了8项研究,共有6301名参与者。结果显示合并敏感性和特异性分别为0.73(95%CI 0.69-0.76)和0.68(95%CI 0.57-0.77)。sROC曲线分析表明AUC为0.74(95%CI 0.70-0.78)。发表偏倚风险较低(p = 0.18)。
本研究结果表明,SII具有相对较高的敏感性,可作为预测接受PCI治疗患者CI-AKI风险的生物标志物。